nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—Cytochrome P450 3A4 Inducers—Topiramate—obesity	0.622	1	CiPCiCtD
Dabrafenib—SLC22A8—Cimetidine—obesity	0.0395	0.22	CbGbCtD
Dabrafenib—SLC22A6—Cimetidine—obesity	0.0275	0.153	CbGbCtD
Dabrafenib—CYP2C8—Bupropion—obesity	0.0247	0.137	CbGbCtD
Dabrafenib—CYP2C8—Cimetidine—obesity	0.0181	0.101	CbGbCtD
Dabrafenib—CYP3A4—Sibutramine—obesity	0.0155	0.0864	CbGbCtD
Dabrafenib—ABCB1—Cimetidine—obesity	0.0123	0.0682	CbGbCtD
Dabrafenib—CYP3A4—Benzphetamine—obesity	0.0118	0.0655	CbGbCtD
Dabrafenib—CYP3A4—Bupropion—obesity	0.01	0.0557	CbGbCtD
Dabrafenib—CYP3A4—Orlistat—obesity	0.00816	0.0454	CbGbCtD
Dabrafenib—CYP3A4—Cimetidine—obesity	0.00734	0.0409	CbGbCtD
Dabrafenib—CYP3A4—Topiramate—obesity	0.00481	0.0268	CbGbCtD
Dabrafenib—NEK11—adrenal gland—obesity	0.0017	0.0654	CbGeAlD
Dabrafenib—LIMK1—adipose tissue—obesity	0.00136	0.0522	CbGeAlD
Dabrafenib—RAF1—hindbrain—obesity	0.00136	0.0521	CbGeAlD
Dabrafenib—LIMK1—adrenal gland—obesity	0.00122	0.0468	CbGeAlD
Dabrafenib—SIK1—islet of Langerhans—obesity	0.0011	0.0423	CbGeAlD
Dabrafenib—SIK1—respiratory system—obesity	0.00104	0.04	CbGeAlD
Dabrafenib—RAF1—islet of Langerhans—obesity	0.000877	0.0337	CbGeAlD
Dabrafenib—BRAF—pituitary gland—obesity	0.000843	0.0324	CbGeAlD
Dabrafenib—BRAF—adipose tissue—obesity	0.00084	0.0323	CbGeAlD
Dabrafenib—RAF1—respiratory system—obesity	0.000828	0.0318	CbGeAlD
Dabrafenib—BRAF—adrenal gland—obesity	0.000753	0.0289	CbGeAlD
Dabrafenib—SLCO1B3—pituitary gland—obesity	0.000727	0.0279	CbGeAlD
Dabrafenib—SIK1—pituitary gland—obesity	0.000706	0.0271	CbGeAlD
Dabrafenib—SIK1—adipose tissue—obesity	0.000703	0.027	CbGeAlD
Dabrafenib—RAF1—adrenal cortex—obesity	0.000695	0.0267	CbGeAlD
Dabrafenib—RAF1—cardiovascular system—obesity	0.000635	0.0244	CbGeAlD
Dabrafenib—SIK1—adrenal gland—obesity	0.000631	0.0242	CbGeAlD
Dabrafenib—BRAF—liver—obesity	0.000589	0.0226	CbGeAlD
Dabrafenib—SLCO1B3—endocrine gland—obesity	0.000563	0.0216	CbGeAlD
Dabrafenib—RAF1—pituitary gland—obesity	0.000562	0.0216	CbGeAlD
Dabrafenib—RAF1—adipose tissue—obesity	0.00056	0.0215	CbGeAlD
Dabrafenib—SIK1—endocrine gland—obesity	0.000547	0.021	CbGeAlD
Dabrafenib—RAF1—digestive system—obesity	0.000527	0.0202	CbGeAlD
Dabrafenib—SLCO1B3—liver—obesity	0.000508	0.0195	CbGeAlD
Dabrafenib—RAF1—adrenal gland—obesity	0.000502	0.0193	CbGeAlD
Dabrafenib—SIK1—liver—obesity	0.000493	0.0189	CbGeAlD
Dabrafenib—RAF1—endocrine gland—obesity	0.000435	0.0167	CbGeAlD
Dabrafenib—SLCO1B1—digestive system—obesity	0.000394	0.0151	CbGeAlD
Dabrafenib—RAF1—liver—obesity	0.000392	0.0151	CbGeAlD
Dabrafenib—SLCO1B1—endocrine gland—obesity	0.000326	0.0125	CbGeAlD
Dabrafenib—SLCO1B1—liver—obesity	0.000294	0.0113	CbGeAlD
Dabrafenib—ABCG2—adrenal cortex—obesity	0.000288	0.011	CbGeAlD
Dabrafenib—CYP2C8—pituitary gland—obesity	0.000239	0.00918	CbGeAlD
Dabrafenib—ABCG2—pituitary gland—obesity	0.000232	0.00892	CbGeAlD
Dabrafenib—ABCG2—adipose tissue—obesity	0.000231	0.00889	CbGeAlD
Dabrafenib—ABCG2—adrenal gland—obesity	0.000208	0.00797	CbGeAlD
Dabrafenib—Urinary tract infection—Sibutramine—obesity	0.000194	0.00226	CcSEcCtD
Dabrafenib—Influenza like illness—Topiramate—obesity	0.000192	0.00224	CcSEcCtD
Dabrafenib—Pancreatitis—Bupropion—obesity	0.000191	0.00223	CcSEcCtD
Dabrafenib—Vomiting—Phenylpropanolamine—obesity	0.000191	0.00223	CcSEcCtD
Dabrafenib—Dizziness—Phentermine—obesity	0.00019	0.00222	CcSEcCtD
Dabrafenib—Haematuria—Sibutramine—obesity	0.00019	0.00222	CcSEcCtD
Dabrafenib—Rash—Phenylpropanolamine—obesity	0.000189	0.00221	CcSEcCtD
Dabrafenib—Dermatitis—Phenylpropanolamine—obesity	0.000189	0.00221	CcSEcCtD
Dabrafenib—Body temperature increased—Cimetidine—obesity	0.000188	0.00219	CcSEcCtD
Dabrafenib—Epistaxis—Sibutramine—obesity	0.000188	0.00219	CcSEcCtD
Dabrafenib—Abdominal discomfort—Bupropion—obesity	0.000187	0.00218	CcSEcCtD
Dabrafenib—Haemoglobin—Orlistat—obesity	0.000186	0.00217	CcSEcCtD
Dabrafenib—CYP2C8—endocrine gland—obesity	0.000185	0.00711	CbGeAlD
Dabrafenib—Haemorrhage—Orlistat—obesity	0.000185	0.00216	CcSEcCtD
Dabrafenib—Vomiting—Phentermine—obesity	0.000183	0.00213	CcSEcCtD
Dabrafenib—Urinary tract disorder—Orlistat—obesity	0.000183	0.00213	CcSEcCtD
Dabrafenib—Oedema peripheral—Orlistat—obesity	0.000182	0.00212	CcSEcCtD
Dabrafenib—Urethral disorder—Orlistat—obesity	0.000181	0.00211	CcSEcCtD
Dabrafenib—Rash—Phentermine—obesity	0.000181	0.00211	CcSEcCtD
Dabrafenib—Dermatitis—Phentermine—obesity	0.000181	0.00211	CcSEcCtD
Dabrafenib—Headache—Phentermine—obesity	0.00018	0.0021	CcSEcCtD
Dabrafenib—Rash maculo-papular—Topiramate—obesity	0.00018	0.0021	CcSEcCtD
Dabrafenib—Haemoglobin—Sibutramine—obesity	0.00018	0.0021	CcSEcCtD
Dabrafenib—ABCB1—islet of Langerhans—obesity	0.000179	0.00687	CbGeAlD
Dabrafenib—Haemorrhage—Sibutramine—obesity	0.000179	0.00209	CcSEcCtD
Dabrafenib—Neoplasm—Topiramate—obesity	0.000179	0.00209	CcSEcCtD
Dabrafenib—Nausea—Phenylpropanolamine—obesity	0.000178	0.00208	CcSEcCtD
Dabrafenib—Oedema peripheral—Sibutramine—obesity	0.000176	0.00206	CcSEcCtD
Dabrafenib—Hyperglycaemia—Bupropion—obesity	0.000176	0.00205	CcSEcCtD
Dabrafenib—Hypersensitivity—Cimetidine—obesity	0.000175	0.00205	CcSEcCtD
Dabrafenib—Infestation—Bupropion—obesity	0.000174	0.00203	CcSEcCtD
Dabrafenib—Infestation NOS—Bupropion—obesity	0.000174	0.00203	CcSEcCtD
Dabrafenib—Diarrhoea—Diethylpropion—obesity	0.000171	0.002	CcSEcCtD
Dabrafenib—Nausea—Phentermine—obesity	0.000171	0.00199	CcSEcCtD
Dabrafenib—Asthenia—Cimetidine—obesity	0.000171	0.00199	CcSEcCtD
Dabrafenib—Stomatitis—Bupropion—obesity	0.000169	0.00198	CcSEcCtD
Dabrafenib—ABCB1—respiratory system—obesity	0.000169	0.00649	CbGeAlD
Dabrafenib—Urinary tract infection—Bupropion—obesity	0.000169	0.00197	CcSEcCtD
Dabrafenib—Eye disorder—Sibutramine—obesity	0.000167	0.00195	CcSEcCtD
Dabrafenib—Immune system disorder—Orlistat—obesity	0.000167	0.00195	CcSEcCtD
Dabrafenib—CYP2C8—liver—obesity	0.000167	0.00641	CbGeAlD
Dabrafenib—Mediastinal disorder—Orlistat—obesity	0.000167	0.00194	CcSEcCtD
Dabrafenib—Dizziness—Diethylpropion—obesity	0.000165	0.00193	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Topiramate—obesity	0.000165	0.00193	CcSEcCtD
Dabrafenib—Epistaxis—Bupropion—obesity	0.000164	0.00191	CcSEcCtD
Dabrafenib—Alopecia—Orlistat—obesity	0.000163	0.00191	CcSEcCtD
Dabrafenib—Diarrhoea—Cimetidine—obesity	0.000163	0.0019	CcSEcCtD
Dabrafenib—Angiopathy—Sibutramine—obesity	0.000162	0.00189	CcSEcCtD
Dabrafenib—ABCG2—liver—obesity	0.000162	0.00623	CbGeAlD
Dabrafenib—Mental disorder—Orlistat—obesity	0.000162	0.00189	CcSEcCtD
Dabrafenib—Immune system disorder—Sibutramine—obesity	0.000162	0.00189	CcSEcCtD
Dabrafenib—Malnutrition—Orlistat—obesity	0.000161	0.00188	CcSEcCtD
Dabrafenib—Chills—Sibutramine—obesity	0.000161	0.00187	CcSEcCtD
Dabrafenib—Arrhythmia—Sibutramine—obesity	0.00016	0.00186	CcSEcCtD
Dabrafenib—Vomiting—Diethylpropion—obesity	0.000159	0.00185	CcSEcCtD
Dabrafenib—Alopecia—Sibutramine—obesity	0.000158	0.00184	CcSEcCtD
Dabrafenib—Rash—Diethylpropion—obesity	0.000158	0.00184	CcSEcCtD
Dabrafenib—Dermatitis—Diethylpropion—obesity	0.000158	0.00184	CcSEcCtD
Dabrafenib—Dizziness—Cimetidine—obesity	0.000157	0.00184	CcSEcCtD
Dabrafenib—Haemoglobin—Bupropion—obesity	0.000157	0.00183	CcSEcCtD
Dabrafenib—Headache—Diethylpropion—obesity	0.000157	0.00183	CcSEcCtD
Dabrafenib—Haemorrhage—Bupropion—obesity	0.000156	0.00182	CcSEcCtD
Dabrafenib—Malnutrition—Sibutramine—obesity	0.000156	0.00182	CcSEcCtD
Dabrafenib—Back pain—Orlistat—obesity	0.000156	0.00182	CcSEcCtD
Dabrafenib—Muscle spasms—Orlistat—obesity	0.000155	0.00181	CcSEcCtD
Dabrafenib—Urinary tract disorder—Bupropion—obesity	0.000154	0.0018	CcSEcCtD
Dabrafenib—Oedema peripheral—Bupropion—obesity	0.000154	0.00179	CcSEcCtD
Dabrafenib—Connective tissue disorder—Bupropion—obesity	0.000153	0.00179	CcSEcCtD
Dabrafenib—Urethral disorder—Bupropion—obesity	0.000153	0.00178	CcSEcCtD
Dabrafenib—CYP3A4—digestive system—obesity	0.000152	0.00583	CbGeAlD
Dabrafenib—Vision blurred—Orlistat—obesity	0.000152	0.00177	CcSEcCtD
Dabrafenib—Vomiting—Cimetidine—obesity	0.000151	0.00176	CcSEcCtD
Dabrafenib—Back pain—Sibutramine—obesity	0.000151	0.00176	CcSEcCtD
Dabrafenib—Rash—Cimetidine—obesity	0.00015	0.00175	CcSEcCtD
Dabrafenib—Dermatitis—Cimetidine—obesity	0.00015	0.00175	CcSEcCtD
Dabrafenib—Muscle spasms—Sibutramine—obesity	0.00015	0.00175	CcSEcCtD
Dabrafenib—Headache—Cimetidine—obesity	0.000149	0.00174	CcSEcCtD
Dabrafenib—Nausea—Diethylpropion—obesity	0.000149	0.00173	CcSEcCtD
Dabrafenib—Vision blurred—Sibutramine—obesity	0.000147	0.00171	CcSEcCtD
Dabrafenib—Eye disorder—Bupropion—obesity	0.000146	0.0017	CcSEcCtD
Dabrafenib—Hyponatraemia—Topiramate—obesity	0.000144	0.00168	CcSEcCtD
Dabrafenib—Anaemia—Sibutramine—obesity	0.000144	0.00168	CcSEcCtD
Dabrafenib—Pain in extremity—Topiramate—obesity	0.000144	0.00168	CcSEcCtD
Dabrafenib—ABCB1—adrenal cortex—obesity	0.000142	0.00545	CbGeAlD
Dabrafenib—Angiopathy—Bupropion—obesity	0.000142	0.00165	CcSEcCtD
Dabrafenib—Nausea—Cimetidine—obesity	0.000141	0.00165	CcSEcCtD
Dabrafenib—Immune system disorder—Bupropion—obesity	0.000141	0.00164	CcSEcCtD
Dabrafenib—Mediastinal disorder—Bupropion—obesity	0.000141	0.00164	CcSEcCtD
Dabrafenib—Cough—Orlistat—obesity	0.00014	0.00164	CcSEcCtD
Dabrafenib—Chills—Bupropion—obesity	0.00014	0.00163	CcSEcCtD
Dabrafenib—Leukopenia—Sibutramine—obesity	0.000139	0.00163	CcSEcCtD
Dabrafenib—Arrhythmia—Bupropion—obesity	0.000139	0.00163	CcSEcCtD
Dabrafenib—Alopecia—Bupropion—obesity	0.000138	0.00161	CcSEcCtD
Dabrafenib—Myalgia—Orlistat—obesity	0.000137	0.0016	CcSEcCtD
Dabrafenib—Mental disorder—Bupropion—obesity	0.000137	0.00159	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000136	0.00159	CcSEcCtD
Dabrafenib—Cough—Sibutramine—obesity	0.000136	0.00159	CcSEcCtD
Dabrafenib—Malnutrition—Bupropion—obesity	0.000136	0.00158	CcSEcCtD
Dabrafenib—Blood creatinine increased—Topiramate—obesity	0.000135	0.00157	CcSEcCtD
Dabrafenib—Hypertension—Sibutramine—obesity	0.000135	0.00157	CcSEcCtD
Dabrafenib—Dry mouth—Orlistat—obesity	0.000134	0.00156	CcSEcCtD
Dabrafenib—Dehydration—Topiramate—obesity	0.000134	0.00156	CcSEcCtD
Dabrafenib—Myalgia—Sibutramine—obesity	0.000133	0.00155	CcSEcCtD
Dabrafenib—Arthralgia—Sibutramine—obesity	0.000133	0.00155	CcSEcCtD
Dabrafenib—Oedema—Orlistat—obesity	0.000131	0.00153	CcSEcCtD
Dabrafenib—Back pain—Bupropion—obesity	0.000131	0.00153	CcSEcCtD
Dabrafenib—Abdominal pain upper—Topiramate—obesity	0.000131	0.00153	CcSEcCtD
Dabrafenib—Hypokalaemia—Topiramate—obesity	0.000131	0.00153	CcSEcCtD
Dabrafenib—Muscle spasms—Bupropion—obesity	0.000131	0.00152	CcSEcCtD
Dabrafenib—Infection—Orlistat—obesity	0.000131	0.00152	CcSEcCtD
Dabrafenib—Dry mouth—Sibutramine—obesity	0.00013	0.00151	CcSEcCtD
Dabrafenib—ABCB1—cardiovascular system—obesity	0.000129	0.00497	CbGeAlD
Dabrafenib—Aspartate aminotransferase increased—Topiramate—obesity	0.000129	0.00151	CcSEcCtD
Dabrafenib—Nervous system disorder—Orlistat—obesity	0.000129	0.0015	CcSEcCtD
Dabrafenib—Nasopharyngitis—Topiramate—obesity	0.000128	0.0015	CcSEcCtD
Dabrafenib—Vision blurred—Bupropion—obesity	0.000128	0.00149	CcSEcCtD
Dabrafenib—Skin disorder—Orlistat—obesity	0.000128	0.00149	CcSEcCtD
Dabrafenib—Oedema—Sibutramine—obesity	0.000127	0.00148	CcSEcCtD
Dabrafenib—Hyperhidrosis—Orlistat—obesity	0.000127	0.00148	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Topiramate—obesity	0.000127	0.00148	CcSEcCtD
Dabrafenib—Infection—Sibutramine—obesity	0.000126	0.00147	CcSEcCtD
Dabrafenib—Anaemia—Bupropion—obesity	0.000126	0.00146	CcSEcCtD
Dabrafenib—CYP3A4—endocrine gland—obesity	0.000125	0.00482	CbGeAlD
Dabrafenib—Thrombocytopenia—Sibutramine—obesity	0.000124	0.00145	CcSEcCtD
Dabrafenib—Skin disorder—Sibutramine—obesity	0.000123	0.00144	CcSEcCtD
Dabrafenib—Hyperhidrosis—Sibutramine—obesity	0.000123	0.00143	CcSEcCtD
Dabrafenib—Pancreatitis—Topiramate—obesity	0.000122	0.00142	CcSEcCtD
Dabrafenib—Leukopenia—Bupropion—obesity	0.000122	0.00142	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Orlistat—obesity	0.00012	0.0014	CcSEcCtD
Dabrafenib—Abdominal discomfort—Topiramate—obesity	0.000119	0.00139	CcSEcCtD
Dabrafenib—Insomnia—Orlistat—obesity	0.000119	0.00139	CcSEcCtD
Dabrafenib—Hypotension—Sibutramine—obesity	0.000119	0.00139	CcSEcCtD
Dabrafenib—Cough—Bupropion—obesity	0.000119	0.00138	CcSEcCtD
Dabrafenib—Hypertension—Bupropion—obesity	0.000117	0.00137	CcSEcCtD
Dabrafenib—Neutropenia—Topiramate—obesity	0.000116	0.00135	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Sibutramine—obesity	0.000116	0.00135	CcSEcCtD
Dabrafenib—Arthralgia—Bupropion—obesity	0.000116	0.00135	CcSEcCtD
Dabrafenib—Myalgia—Bupropion—obesity	0.000116	0.00135	CcSEcCtD
Dabrafenib—Insomnia—Sibutramine—obesity	0.000115	0.00134	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000115	0.00134	CcSEcCtD
Dabrafenib—ABCB1—pituitary gland—obesity	0.000115	0.0044	CbGeAlD
Dabrafenib—Decreased appetite—Orlistat—obesity	0.000114	0.00133	CcSEcCtD
Dabrafenib—ABCB1—adipose tissue—obesity	0.000114	0.00438	CbGeAlD
Dabrafenib—Gastrointestinal disorder—Orlistat—obesity	0.000113	0.00132	CcSEcCtD
Dabrafenib—Fatigue—Orlistat—obesity	0.000113	0.00132	CcSEcCtD
Dabrafenib—Dry mouth—Bupropion—obesity	0.000113	0.00132	CcSEcCtD
Dabrafenib—CYP3A4—liver—obesity	0.000113	0.00434	CbGeAlD
Dabrafenib—Hyperglycaemia—Topiramate—obesity	0.000112	0.00131	CcSEcCtD
Dabrafenib—Oedema—Bupropion—obesity	0.000111	0.00129	CcSEcCtD
Dabrafenib—Infestation NOS—Topiramate—obesity	0.000111	0.00129	CcSEcCtD
Dabrafenib—Infestation—Topiramate—obesity	0.000111	0.00129	CcSEcCtD
Dabrafenib—Decreased appetite—Sibutramine—obesity	0.000111	0.00129	CcSEcCtD
Dabrafenib—Infection—Bupropion—obesity	0.00011	0.00128	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Sibutramine—obesity	0.00011	0.00128	CcSEcCtD
Dabrafenib—Renal failure—Topiramate—obesity	0.000109	0.00127	CcSEcCtD
Dabrafenib—Constipation—Sibutramine—obesity	0.000109	0.00127	CcSEcCtD
Dabrafenib—Nervous system disorder—Bupropion—obesity	0.000109	0.00127	CcSEcCtD
Dabrafenib—Thrombocytopenia—Bupropion—obesity	0.000109	0.00127	CcSEcCtD
Dabrafenib—Stomatitis—Topiramate—obesity	0.000108	0.00126	CcSEcCtD
Dabrafenib—Skin disorder—Bupropion—obesity	0.000108	0.00126	CcSEcCtD
Dabrafenib—Urinary tract infection—Topiramate—obesity	0.000108	0.00126	CcSEcCtD
Dabrafenib—ABCB1—digestive system—obesity	0.000107	0.00413	CbGeAlD
Dabrafenib—Gastrointestinal pain—Orlistat—obesity	0.000107	0.00125	CcSEcCtD
Dabrafenib—Hyperhidrosis—Bupropion—obesity	0.000107	0.00125	CcSEcCtD
Dabrafenib—Haematuria—Topiramate—obesity	0.000106	0.00123	CcSEcCtD
Dabrafenib—Epistaxis—Topiramate—obesity	0.000104	0.00122	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Sibutramine—obesity	0.000104	0.00121	CcSEcCtD
Dabrafenib—Abdominal pain—Orlistat—obesity	0.000104	0.00121	CcSEcCtD
Dabrafenib—Body temperature increased—Orlistat—obesity	0.000104	0.00121	CcSEcCtD
Dabrafenib—Hypotension—Bupropion—obesity	0.000104	0.00121	CcSEcCtD
Dabrafenib—ABCB1—adrenal gland—obesity	0.000102	0.00393	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Bupropion—obesity	0.000101	0.00118	CcSEcCtD
Dabrafenib—Abdominal pain—Sibutramine—obesity	0.000101	0.00117	CcSEcCtD
Dabrafenib—Body temperature increased—Sibutramine—obesity	0.000101	0.00117	CcSEcCtD
Dabrafenib—Insomnia—Bupropion—obesity	0.0001	0.00117	CcSEcCtD
Dabrafenib—Haemoglobin—Topiramate—obesity	9.99e-05	0.00117	CcSEcCtD
Dabrafenib—Haemorrhage—Topiramate—obesity	9.94e-05	0.00116	CcSEcCtD
Dabrafenib—Urinary tract disorder—Topiramate—obesity	9.82e-05	0.00114	CcSEcCtD
Dabrafenib—Oedema peripheral—Topiramate—obesity	9.79e-05	0.00114	CcSEcCtD
Dabrafenib—Connective tissue disorder—Topiramate—obesity	9.77e-05	0.00114	CcSEcCtD
Dabrafenib—Urethral disorder—Topiramate—obesity	9.74e-05	0.00114	CcSEcCtD
Dabrafenib—Hypersensitivity—Orlistat—obesity	9.68e-05	0.00113	CcSEcCtD
Dabrafenib—Decreased appetite—Bupropion—obesity	9.64e-05	0.00112	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Bupropion—obesity	9.57e-05	0.00112	CcSEcCtD
Dabrafenib—Fatigue—Bupropion—obesity	9.56e-05	0.00111	CcSEcCtD
Dabrafenib—Constipation—Bupropion—obesity	9.48e-05	0.00111	CcSEcCtD
Dabrafenib—Asthenia—Orlistat—obesity	9.43e-05	0.0011	CcSEcCtD
Dabrafenib—Hypersensitivity—Sibutramine—obesity	9.37e-05	0.00109	CcSEcCtD
Dabrafenib—Pruritus—Orlistat—obesity	9.29e-05	0.00108	CcSEcCtD
Dabrafenib—Eye disorder—Topiramate—obesity	9.29e-05	0.00108	CcSEcCtD
Dabrafenib—Asthenia—Sibutramine—obesity	9.12e-05	0.00106	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Bupropion—obesity	9.06e-05	0.00106	CcSEcCtD
Dabrafenib—Angiopathy—Topiramate—obesity	9.02e-05	0.00105	CcSEcCtD
Dabrafenib—Pruritus—Sibutramine—obesity	9e-05	0.00105	CcSEcCtD
Dabrafenib—Diarrhoea—Orlistat—obesity	8.99e-05	0.00105	CcSEcCtD
Dabrafenib—Immune system disorder—Topiramate—obesity	8.98e-05	0.00105	CcSEcCtD
Dabrafenib—Mediastinal disorder—Topiramate—obesity	8.96e-05	0.00104	CcSEcCtD
Dabrafenib—Chills—Topiramate—obesity	8.92e-05	0.00104	CcSEcCtD
Dabrafenib—ABCB1—endocrine gland—obesity	8.88e-05	0.00341	CbGeAlD
Dabrafenib—Alopecia—Topiramate—obesity	8.78e-05	0.00102	CcSEcCtD
Dabrafenib—Body temperature increased—Bupropion—obesity	8.76e-05	0.00102	CcSEcCtD
Dabrafenib—Abdominal pain—Bupropion—obesity	8.76e-05	0.00102	CcSEcCtD
Dabrafenib—Mental disorder—Topiramate—obesity	8.71e-05	0.00102	CcSEcCtD
Dabrafenib—Diarrhoea—Sibutramine—obesity	8.7e-05	0.00101	CcSEcCtD
Dabrafenib—Dizziness—Orlistat—obesity	8.69e-05	0.00101	CcSEcCtD
Dabrafenib—Erythema—Topiramate—obesity	8.65e-05	0.00101	CcSEcCtD
Dabrafenib—Malnutrition—Topiramate—obesity	8.65e-05	0.00101	CcSEcCtD
Dabrafenib—Dizziness—Sibutramine—obesity	8.41e-05	0.000981	CcSEcCtD
Dabrafenib—Back pain—Topiramate—obesity	8.37e-05	0.000976	CcSEcCtD
Dabrafenib—Vomiting—Orlistat—obesity	8.35e-05	0.000974	CcSEcCtD
Dabrafenib—Muscle spasms—Topiramate—obesity	8.32e-05	0.00097	CcSEcCtD
Dabrafenib—Rash—Orlistat—obesity	8.28e-05	0.000966	CcSEcCtD
Dabrafenib—Dermatitis—Orlistat—obesity	8.28e-05	0.000965	CcSEcCtD
Dabrafenib—Headache—Orlistat—obesity	8.23e-05	0.00096	CcSEcCtD
Dabrafenib—Hypersensitivity—Bupropion—obesity	8.17e-05	0.000953	CcSEcCtD
Dabrafenib—Vision blurred—Topiramate—obesity	8.15e-05	0.000951	CcSEcCtD
Dabrafenib—Vomiting—Sibutramine—obesity	8.08e-05	0.000943	CcSEcCtD
Dabrafenib—Rash—Sibutramine—obesity	8.02e-05	0.000935	CcSEcCtD
Dabrafenib—Dermatitis—Sibutramine—obesity	8.01e-05	0.000934	CcSEcCtD
Dabrafenib—ABCB1—liver—obesity	8e-05	0.00307	CbGeAlD
Dabrafenib—Anaemia—Topiramate—obesity	8e-05	0.000933	CcSEcCtD
Dabrafenib—Headache—Sibutramine—obesity	7.97e-05	0.000929	CcSEcCtD
Dabrafenib—Asthenia—Bupropion—obesity	7.95e-05	0.000928	CcSEcCtD
Dabrafenib—Pruritus—Bupropion—obesity	7.84e-05	0.000915	CcSEcCtD
Dabrafenib—Nausea—Orlistat—obesity	7.8e-05	0.00091	CcSEcCtD
Dabrafenib—Leukopenia—Topiramate—obesity	7.75e-05	0.000903	CcSEcCtD
Dabrafenib—Diarrhoea—Bupropion—obesity	7.58e-05	0.000885	CcSEcCtD
Dabrafenib—Nausea—Sibutramine—obesity	7.55e-05	0.000881	CcSEcCtD
Dabrafenib—Cough—Topiramate—obesity	7.55e-05	0.000881	CcSEcCtD
Dabrafenib—Hypertension—Topiramate—obesity	7.47e-05	0.000871	CcSEcCtD
Dabrafenib—Myalgia—Topiramate—obesity	7.37e-05	0.000859	CcSEcCtD
Dabrafenib—Arthralgia—Topiramate—obesity	7.37e-05	0.000859	CcSEcCtD
Dabrafenib—Dizziness—Bupropion—obesity	7.33e-05	0.000855	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	7.32e-05	0.000853	CcSEcCtD
Dabrafenib—Dry mouth—Topiramate—obesity	7.2e-05	0.00084	CcSEcCtD
Dabrafenib—Oedema—Topiramate—obesity	7.06e-05	0.000824	CcSEcCtD
Dabrafenib—Vomiting—Bupropion—obesity	7.05e-05	0.000822	CcSEcCtD
Dabrafenib—Infection—Topiramate—obesity	7.02e-05	0.000818	CcSEcCtD
Dabrafenib—Rash—Bupropion—obesity	6.99e-05	0.000815	CcSEcCtD
Dabrafenib—Dermatitis—Bupropion—obesity	6.98e-05	0.000814	CcSEcCtD
Dabrafenib—Headache—Bupropion—obesity	6.94e-05	0.00081	CcSEcCtD
Dabrafenib—Nervous system disorder—Topiramate—obesity	6.93e-05	0.000808	CcSEcCtD
Dabrafenib—Thrombocytopenia—Topiramate—obesity	6.91e-05	0.000806	CcSEcCtD
Dabrafenib—Skin disorder—Topiramate—obesity	6.86e-05	0.0008	CcSEcCtD
Dabrafenib—Hyperhidrosis—Topiramate—obesity	6.83e-05	0.000796	CcSEcCtD
Dabrafenib—Hypotension—Topiramate—obesity	6.6e-05	0.00077	CcSEcCtD
Dabrafenib—Nausea—Bupropion—obesity	6.58e-05	0.000768	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Topiramate—obesity	6.43e-05	0.00075	CcSEcCtD
Dabrafenib—Insomnia—Topiramate—obesity	6.39e-05	0.000745	CcSEcCtD
Dabrafenib—Decreased appetite—Topiramate—obesity	6.14e-05	0.000716	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Topiramate—obesity	6.1e-05	0.000711	CcSEcCtD
Dabrafenib—Fatigue—Topiramate—obesity	6.09e-05	0.00071	CcSEcCtD
Dabrafenib—Constipation—Topiramate—obesity	6.04e-05	0.000704	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Topiramate—obesity	5.77e-05	0.000674	CcSEcCtD
Dabrafenib—Abdominal pain—Topiramate—obesity	5.58e-05	0.000651	CcSEcCtD
Dabrafenib—Body temperature increased—Topiramate—obesity	5.58e-05	0.000651	CcSEcCtD
Dabrafenib—Hypersensitivity—Topiramate—obesity	5.2e-05	0.000607	CcSEcCtD
Dabrafenib—Asthenia—Topiramate—obesity	5.07e-05	0.000591	CcSEcCtD
Dabrafenib—Pruritus—Topiramate—obesity	5e-05	0.000583	CcSEcCtD
Dabrafenib—Diarrhoea—Topiramate—obesity	4.83e-05	0.000564	CcSEcCtD
Dabrafenib—Dizziness—Topiramate—obesity	4.67e-05	0.000545	CcSEcCtD
Dabrafenib—Vomiting—Topiramate—obesity	4.49e-05	0.000524	CcSEcCtD
Dabrafenib—Rash—Topiramate—obesity	4.45e-05	0.000519	CcSEcCtD
Dabrafenib—Dermatitis—Topiramate—obesity	4.45e-05	0.000519	CcSEcCtD
Dabrafenib—Headache—Topiramate—obesity	4.42e-05	0.000516	CcSEcCtD
Dabrafenib—Nausea—Topiramate—obesity	4.19e-05	0.000489	CcSEcCtD
Dabrafenib—RAF1—Signaling Pathways—IRS2—obesity	2.32e-06	2.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGT—obesity	2.31e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SCARB1—obesity	2.31e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—obesity	2.31e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—obesity	2.3e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UCP3—obesity	2.28e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UCP2—obesity	2.28e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ECHS1—obesity	2.28e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD11B1—obesity	2.28e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—obesity	2.28e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—obesity	2.27e-06	2.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—obesity	2.27e-06	2.61e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—obesity	2.27e-06	2.61e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—obesity	2.27e-06	2.61e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—obesity	2.26e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—obesity	2.25e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CAV1—obesity	2.25e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADH1B—obesity	2.24e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SREBF1—obesity	2.24e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOA1—obesity	2.24e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—obesity	2.24e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—obesity	2.24e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—obesity	2.24e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A4—obesity	2.23e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GCG—obesity	2.23e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—obesity	2.23e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—obesity	2.22e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPAM—obesity	2.21e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACSL1—obesity	2.21e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARGC1B—obesity	2.21e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYCS—obesity	2.2e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—obesity	2.2e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—INS—obesity	2.18e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT2—obesity	2.18e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—obesity	2.17e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GOT1—obesity	2.16e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GGT1—obesity	2.16e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FADS1—obesity	2.14e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PCK1—obesity	2.14e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HADH—obesity	2.14e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—obesity	2.14e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—F2—obesity	2.14e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCB—obesity	2.14e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FASN—obesity	2.14e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—obesity	2.14e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NCOA1—obesity	2.13e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—obesity	2.13e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BAD—obesity	2.11e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—STK11—obesity	2.1e-06	2.41e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP19A1—obesity	2.1e-06	2.41e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACP5—obesity	2.09e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—obesity	2.07e-06	2.39e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—obesity	2.06e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2E1—obesity	2.05e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—obesity	2.05e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—obesity	2.05e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—G6PD—obesity	2.03e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—obesity	2.03e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NQO1—obesity	2.03e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—obesity	2.03e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IRS1—obesity	2.02e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—INS—obesity	2.02e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HK1—obesity	2.01e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SREBF2—obesity	2.01e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—obesity	2e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—obesity	1.99e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—obesity	1.97e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—obesity	1.97e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—COMT—obesity	1.95e-06	2.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—obesity	1.95e-06	2.24e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A4—obesity	1.94e-06	2.24e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCG—obesity	1.94e-06	2.24e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPA—obesity	1.94e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—INS—obesity	1.94e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARGC1A—obesity	1.92e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNB3—obesity	1.92e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYCS—obesity	1.92e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—obesity	1.92e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—obesity	1.92e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3R1—obesity	1.91e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—obesity	1.91e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—obesity	1.91e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPIN1—obesity	1.9e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GOT1—obesity	1.88e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GGT1—obesity	1.88e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—obesity	1.88e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—obesity	1.87e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—obesity	1.87e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNAS—obesity	1.87e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT2—obesity	1.87e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA5—obesity	1.86e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NCOA1—obesity	1.86e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—obesity	1.85e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOB—obesity	1.83e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP19A1—obesity	1.83e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—STK11—obesity	1.83e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—obesity	1.8e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—obesity	1.78e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC22A1—obesity	1.77e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CLOCK—obesity	1.77e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—obesity	1.77e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3R1—obesity	1.77e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—obesity	1.77e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—obesity	1.75e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LPL—obesity	1.75e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—obesity	1.75e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—obesity	1.75e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TYK2—obesity	1.73e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—obesity	1.73e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SULT2A1—obesity	1.73e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GLP1R—obesity	1.73e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RHOA—obesity	1.72e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—obesity	1.71e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DPYD—obesity	1.7e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—COMT—obesity	1.7e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3R1—obesity	1.7e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—obesity	1.7e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNB3—obesity	1.68e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARGC1A—obesity	1.68e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—obesity	1.67e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD36—obesity	1.66e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PRKAR2B—obesity	1.64e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—obesity	1.64e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNAS—obesity	1.63e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—obesity	1.63e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—DCN—obesity	1.63e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—obesity	1.62e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—obesity	1.62e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—obesity	1.62e-06	1.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—obesity	1.61e-06	1.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—obesity	1.61e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—obesity	1.6e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—obesity	1.6e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOB—obesity	1.6e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CPT1A—obesity	1.58e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—obesity	1.58e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—obesity	1.57e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—obesity	1.57e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAMPT—obesity	1.55e-06	1.78e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARA—obesity	1.55e-06	1.78e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LIPC—obesity	1.54e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCK—obesity	1.54e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOC3—obesity	1.53e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPL—obesity	1.53e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGT—obesity	1.5e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—obesity	1.49e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CETP—obesity	1.49e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—obesity	1.48e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SDC1—obesity	1.47e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—obesity	1.47e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—obesity	1.45e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOA1—obesity	1.45e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD36—obesity	1.45e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKR1C3—obesity	1.45e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—obesity	1.43e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SCARB1—obesity	1.42e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—obesity	1.39e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—obesity	1.38e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SREBF1—obesity	1.38e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—obesity	1.37e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—obesity	1.37e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—obesity	1.36e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARA—obesity	1.35e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT2—obesity	1.34e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—obesity	1.33e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—obesity	1.33e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—obesity	1.32e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FASN—obesity	1.32e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—obesity	1.31e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—obesity	1.31e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—obesity	1.31e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGT—obesity	1.31e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—obesity	1.28e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—obesity	1.28e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—obesity	1.27e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOA1—obesity	1.26e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2E1—obesity	1.26e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—obesity	1.26e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INS—obesity	1.25e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NQO1—obesity	1.25e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—obesity	1.22e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—obesity	1.21e-06	1.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—obesity	1.21e-06	1.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—obesity	1.21e-06	1.39e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCG—obesity	1.2e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A4—obesity	1.2e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYCS—obesity	1.18e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—obesity	1.16e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GOT1—obesity	1.16e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GGT1—obesity	1.16e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—obesity	1.15e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—obesity	1.15e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA1—obesity	1.14e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—obesity	1.13e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STK11—obesity	1.13e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP19A1—obesity	1.13e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—obesity	1.13e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—obesity	1.12e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—obesity	1.12e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—obesity	1.11e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—obesity	1.1e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3R1—obesity	1.1e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—obesity	1.1e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INS—obesity	1.09e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—obesity	1.08e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COMT—obesity	1.05e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARGC1A—obesity	1.03e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNB3—obesity	1.03e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—obesity	1.03e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—obesity	1.02e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—obesity	1.01e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—obesity	1.01e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNAS—obesity	1.01e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—obesity	1e-06	1.15e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—obesity	9.97e-07	1.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOB—obesity	9.85e-07	1.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—obesity	9.58e-07	1.1e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3R1—obesity	9.58e-07	1.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—obesity	9.56e-07	1.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPL—obesity	9.4e-07	1.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—obesity	9.17e-07	1.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD36—obesity	8.93e-07	1.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—obesity	8.85e-07	1.02e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—obesity	8.8e-07	1.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—obesity	8.76e-07	1.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—obesity	8.47e-07	9.74e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—obesity	8.47e-07	9.74e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARA—obesity	8.31e-07	9.56e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—obesity	8.15e-07	9.38e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGT—obesity	8.04e-07	9.25e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—obesity	7.88e-07	9.07e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—obesity	7.81e-07	8.99e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—obesity	7.81e-07	8.98e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA1—obesity	7.79e-07	8.96e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—obesity	7.11e-07	8.18e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—obesity	6.86e-07	7.9e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—obesity	6.77e-07	7.79e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INS—obesity	6.73e-07	7.75e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—obesity	6.25e-07	7.19e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—obesity	6.19e-07	7.12e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—obesity	6.17e-07	7.1e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3R1—obesity	5.9e-07	6.79e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—obesity	5.9e-07	6.79e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—obesity	5.45e-07	6.27e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—obesity	5.4e-07	6.21e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—obesity	5.39e-07	6.2e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—obesity	5.06e-07	5.82e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—obesity	4.41e-07	5.07e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—obesity	3.32e-07	3.82e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—obesity	2.71e-07	3.12e-06	CbGpPWpGaD
